7 results about "Nuclear localization sequence" patented technology

This invention discloses a protease-responsive GPCR receptor and its applications. The protease-responsive GPCR receptor of this invention comprises an extracellular protease recognition domain, a transmembrane domain, and an intracellular signaling domain; the extracellular protease recognition domain contains a peptide hydrolyzed by the protease; the intracellular signaling domain contains an HCV enzyme hydrolyzed peptide, a nuclear localization sequence (NLS), a Cas protease, and a coupled nuclear transcription factor. This protease-responsive GPCR receptor can induce endogenous dCas9 assembly into the nucleus and activate the chimeric antigen receptor signaling pathway in natural killer cells in response to extracellular proteases, providing a new solution for developing novel precision immunotherapy.

The invention discloses a USAG-1 recombinant protein targeted delivery system based on multi-enzyme logic gating and a preparation method, and mainly relates to crossing of biological medicine and nanotechnology. Comprising the following steps: S1, a C-terminal fusion nuclear localization sequence PKKKRKV of a recombinant USAG-1 protein expressed by CHO cells, and the purity of the recombinant USAG-1 protein is greater than or equal to 98%; s2, preparing core-shell structure nanoparticles, wherein the core is PLGA loaded BMP-2, and the drug loading capacity is 2.5-4.2 [mu] g / mg; the outer-layer lipid membrane is composed of DSPC / DSPG according to the ratio of 7: 3, and the surface embedded USAG-1 molecular density is greater than or equal to 1 * 10 / mu m < 2 >; s3, the surface co-modified EGFR antibody and the RGDfK peptide are connected through a thiol-maleimide bond and a PEG2000 spacer arm according to the molecular ratio of 1: 1.6 + / -0.2, the coding sequence of the recombinant USAG-1 is regulated and controlled by an MMP-9 response promoter, and the promoter is located in MMP-9gt; and the expression is activated at 20nM. The system has the beneficial effects that time-space precise delivery of the bone metabolism related protein USAG-1 is realized through a multi-enzyme logic gating mechanism, and the system is suitable for treatment of bone metabolism disorder diseases such as osteosarcoma and alveolar bone defect.

Disclosed are a novel nuclear localization sequence (NLS) mutant and a method for improving biosynthetic efficiency using same, belonging to the field of bioengineering. According to the present disclosure, a novel NLS is screened out, and recombinant yeast with improved metabolite synthesis efficiency is constructed by applying the NLS obtained through screening, which provides key technical support for developing a high-yield, stable and cost-effective yeast biosynthesis platform, and facilitates the use of recombinant yeast as a cell factory for large-scale industrial biomanufacturing.

The application relates to the technical field of biological medicine engineering, and provides a preparation method and application of a scorpion toxin-derived transmembrane polypeptide. The OpiCalcin1 polypeptide is optimized in a truncation mode, two polypeptides Opi1 17-33 CSKKCKRRGTNPEKRCR and Opi1 23-33 RRGTNPEKRCR with excellent transmembrane function and low cytotoxicity are provided. Through experiment verification, the two cell transmembrane peptides have excellent transmembrane effect and low cytotoxicity, meanwhile, the defects of time-consuming and laborious in synthesizing the complete sequence of scorpion toxin OpiCalcin1 are overcome, the cell transmembrane peptides can be used for preparing drug, nuclear localization sequence and probe transport carriers, and the targeting efficiency is improved. Compared with traditional scorpion toxin medicine, the synthesis of the scorpion toxin to explore the transmembrane activity provides a new selection for the drug carrier.

The present technology relates to the field of drug delivery and provides a molecule comprising or consisting of at least one protein-based carrier building unit, wherein the protein-based carrier building unit comprises at least one, preferably at least two attachment points or conjugation sites. In particular, the present technology provides a molecule comprising at least one protein-based building unit, wherein the at least one protein-based building unit: a) comprises at least one conjugation site or attachment point; b) has a molecular weight of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in aqueous solution at room temperature; and does not specifically bind to any human protein or binds to one or more human proteins with a K D value of more than 5 x 10 ‑4 mol / liter, wherein the molecule further comprises at least one nuclear localization sequence (NLS) covalently linked to the at least one conjugation site or attachment point comprised in the protein-based carrier building unit, directly or via a linker, wherein the NLS preferably comprises or consists of SEQ ID NO: 221.

This invention discloses a shuttle peptide targeting YY1S247 phosphorylation and its application. The sequence of the shuttle peptide is shown in SEQ ID NO: 1. RQIKIWFQNRRMKWKK is a part of the Drosophila melanogaster tentacles peptide, used to provide cell penetration; PKKKRKV is the nuclear localization sequence of the SV40 large T antigen, used to guide the peptide into the cell nucleus; QIIGENSPPDYSE is the surrounding sequence of the YY1S247 site. The results show that the shuttle peptide (CPP) of this invention can competitively and specifically inhibit phosphorylation at the YY1S247 site, thereby inhibiting CD24 expression and enhancing the therapeutic effect of EGFR-TKIs.

The present invention relates to the field of gene transfer, in particular, targeted gene transfer and enzymes for use in targeted gene transfer. In particular, the present invention provides a nucleic acid encoding a fusion protein having serine integrase activity, wherein the fusion protein comprises a serine integrase consisting of a protein having at least 80% sequence identity to the large serine integrase Pa01 and a nuclear localization sequence at the C-terminus of the serine integrase. The invention further provides a fusion protein encoded by said nucleic acid as well as methods of preparing an engineered cell using the nucleic acids and / or fusion proteins of the invention. Finally, the present invention provides various pharmaceutical compositions and their use in treating a disease or disorder.